Molecule Screening Engine reference profile.
Which candidate molecules from a screening library are worth advancing to the next stage of experimental validation?
Overview
Narrows huge virtual libraries down to a shortlist worth spending wet-lab budget on.
Who owns this decision
VP Drug Discovery, Head of Computational Chemistry
What this Specialist Model actually does
Decision: Which candidate molecules from a screening library are worth advancing to the next stage of experimental validation?
The final taxonomy records 6 supporting or external components, but it doesn't promote an Oumi-owned specialist model for this engine.
Who uses this Specialist Model
- VP Drug Discovery
- Head of Computational Chemistry
- Chief Scientific Officer
- Director of Preclinical Research
Where the specialist model sits
The final taxonomy records 6 supporting or external components, but it doesn't promote an Oumi-owned specialist model for this engine.
Retrieval over internal assay history and literature
Supporting component
Ranking layer combining predicted properties into a priority score
Supporting component
Chemist review and override interface
Supporting component
How Oumi connects to your stack →
Molecular representation/featurization pipeline (fingerprints, graph embeddings)
Supporting component
How Oumi connects to your stack →
Dedicated property-prediction models (ADMET, docking) outside the general LLM stack
Supporting component
General reasoning model
Supporting component
General reasoning model for literature synthesis and rationale generation
How to evaluate and improve it
Evaluation
- Enrichment factor (true actives found in top-ranked subset)
- Correlation between predicted and assayed properties
- False-negative rate on known actives (held-out)
Feedback signals
- Wet-lab assay result confirms or contradicts prediction
- Molecule advances to next stage or is dropped
- Synthesis difficulty encountered that wasn't predicted
- Toxicity or off-target effect discovered downstream
- Chemist override of a priority ranking
- Patent landscape change affecting viability


